Journal of Thrombosis and Thrombolysis

, Volume 31, Issue 2, pp 139–145 | Cite as

Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy

  • Charles L. Campbell
  • Steven R. Steinhubl
  • William C. Hooper
  • Joseph Jozic
  • Susan S. Smyth
  • Debra Bernstein
  • Christine De Staercke
  • George Syros
  • Brian H. Negus
  • Thomas Stuckey
  • Gregg W. Stone
  • Roxana Mehran
  • George Dangas
Article

Abstract

Bleeding events have been associated with adverse early and late outcomes in virtually all clinical settings. The mechanism behind this observation remains poorly understood. We sought to determine if the reason might be the provocation of an inflammatory response by bleeding events. In a formal substudy of the ACUITY trial, plasma samples of a range of biomarkers were collected at baseline, discharge, 30 days, and 1 year from 192 patients with acute coronary syndromes (ACS) and were analyzed in a central core laboratory. Temporal changes in biomarker levels were assessed in patients who experienced in-hospital hemorrhagic events, recurrent ischemic events, or neither. Sixteen patients were excluded from the study (7 with incomplete samples, 5 undergoing coronary artery bypass grafting (CABG) during index hospitalization; 1 had both bleeding and ischemic events). Median high sensitivity C-reactive protein (hs-CRP) levels (mg/l) increased significantly more from admission to discharge among the 9 patients who experienced an in-hospital major bleed compared to either the 9 patients who had a recurrent ischemic event (+6.0 vs. +0.70, P = 0.04) or the 151 patients who had no event (+6.0 vs. +0.60, P = 0.003). Compared to patients with no in-hospital events, median interleukin-6 (IL-6) levels (pg/ml) increased from admission to hospital discharge non-significantly in those with a bleeding event (+0.92 vs. +2.46, P = 0.55) and in those who experienced an in-hospital recurrent ischemic event (+0.92 vs. +3.60, P = 0.09). These data suggest that major bleeding is associated with development of a pro-inflammatory state. If confirmed, this mechanism may in part explain the poor prognosis of patients experiencing an acute hemorrhagic event.

Keywords

Acute coronary syndromes Bleeding events Highly sensitive C-reactive protein Interleukin-1 

Supplementary material

11239_2010_513_MOESM1_ESM.doc (151 kb)
Supplementary material 1 (DOC 151 kb)

References

  1. 1.
    Rao SV, Eikelboom JA, Granger CB, Harrington RA, Califf RM, Bassand JP (2007) Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 28:1193–1204CrossRefPubMedGoogle Scholar
  2. 2.
    Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, Dangas GD, Lincoff AM, White HD, Moses JW, King SB III, Ohman EM, Stone GW (2007) Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 49:1362–1368CrossRefPubMedGoogle Scholar
  3. 3.
    Yang X, Alexander KP, Chen AY, Roe MT, Brindis RG, Rao SV, Gibler WB, Ohman EM, Peterson ED (2005) The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE national quality improvement initiative. J Am Coll Cardiol 46:1490–1495CrossRefPubMedGoogle Scholar
  4. 4.
    Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, Moliterno DJ, Lindblad L, Pieper K, Topol EJ, Stamler JS, Califf RM (2004) Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. Jama 292:1555–1562CrossRefPubMedGoogle Scholar
  5. 5.
    Nikolsky E, Mehran R, Sadeghi HM, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Stone GW (2009) Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (controlled Abciximab and device investigation to lower late angioplasty complications) Trial. JACC Cardiovasc Interv 2:624–632CrossRefPubMedGoogle Scholar
  6. 6.
    Mehran R, Pocock SJ, Stone GW, Clayton TC, Dangas GD, Feit F, Manoukian SV, Nikolsky E, Lansky AJ, Kirtane A, White HD, Colombo A, Ware JH, Moses JW, Ohman EM (2009) Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 30:1457–1466CrossRefPubMedGoogle Scholar
  7. 7.
    Roe MT, Chen AY, Mehta RH, Li Y, Brindis RG, Smith SC Jr, Rumsfeld JS, Gibler WB, Ohman EM, Peterson ED (2007) Influence of inpatient service specialty on care processes and outcomes for patients with non ST-segment elevation acute coronary syndromes. Circulation 116:1153–1161CrossRefPubMedGoogle Scholar
  8. 8.
    Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358:2218–2230CrossRefPubMedGoogle Scholar
  9. 9.
    Doyle BJ, Rihal CS, Gastineau DA, Holmes DR Jr (2009) Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol 53:2019–2027CrossRefPubMedGoogle Scholar
  10. 10.
    Fransen E, Maessen J, Dentener M, Senden N, Buurman W (1999) Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. Chest 116:1233–1239CrossRefPubMedGoogle Scholar
  11. 11.
    Wagener FA, Eggert A, Boerman OC, Oyen WJ, Verhofstad A, Abraham NG, Adema G, van Kooyk Y, de Witte T, Figdor CG (2001) Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood 98:1802–1811CrossRefPubMedGoogle Scholar
  12. 12.
    Jeney V, Balla J, Yachie A, Varga Z, Vercellotti GM, Eaton JW, Balla G (2002) Pro-oxidant and cytotoxic effects of circulating heme. Blood 100:879–887CrossRefPubMedGoogle Scholar
  13. 13.
    Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Manoukian SV, Fahy M, Clayton TC, Mehran R, Pocock SJ (2007) Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. Jama 298:2497–2506CrossRefPubMedGoogle Scholar
  14. 14.
    Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, Lansky AJ, Lincoff AM, Mehran R, Moses JW, Ohman M, White HD (2004) Acute catheterization and urgent intervention triage strategY (ACUITY) trial: study design and rationale. Am Heart J 148:764–775CrossRefPubMedGoogle Scholar
  15. 15.
    Krivoy N, Adler Z, Saloma R, Hawadie A, Azzam ZS (2008) Targeting C-reactive protein levels using high-dose atorvastatin before coronary artery bypass graft surgery. Exp Clin Cardiol 13:171–174PubMedGoogle Scholar
  16. 16.
    Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355:2203–2216CrossRefPubMedGoogle Scholar
  17. 17.
    Aoki J, Lansky AJ, Mehran R, Moses J, Bertrand ME, McLaurin BT, Cox DA, Lincoff AM, Ohman EM, White HD, Parise H, Leon MB, Stone GW (2009) Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the acute catheterization and urgent intervention triage strategy trial. Circulation 119:687–698CrossRefPubMedGoogle Scholar
  18. 18.
    Wang TY, Xiao L, Alexander KP, Rao SV, Kosiborod MN, Rumsfeld JS, Spertus JA, Peterson ED (2008) Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. Circulation 118:2139–2145CrossRefPubMedGoogle Scholar
  19. 19.
    Spencer FA, Moscucci M, Granger CB, Gore JM, Goldberg RJ, Steg PG, Goodman SG, Budaj A, FitzGerald G, Fox KA (2007) Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation 116:2793–2801CrossRefPubMedGoogle Scholar
  20. 20.
    Yang J, Wang J, Zhu S, Chen X, Wu H, Yang D, Zhang J (2008) C-reactive protein augments hypoxia-induced apoptosis through mitochondrion-dependent pathway in cardiac myocytes. Mol Cell Biochem 310:215–226CrossRefPubMedGoogle Scholar
  21. 21.
    Woodward M, Lowe GD, Francis LM, Rumley A, Cobbe SM (2004) A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost 2:1934–1940CrossRefPubMedGoogle Scholar
  22. 22.
    Welch HG, Meehan KR, Goodnough LT (1992) Prudent strategies for elective red blood cell transfusion. Ann Intern Med 116:393–402PubMedGoogle Scholar
  23. 23.
    Shiga T, Maeda N, Kon K (1990) Erythrocyte rheology. Crit Rev Oncol Hematol 10:9–48CrossRefPubMedGoogle Scholar
  24. 24.
    Zamboni P, Lanzara S, Mascoli F, Caggiati A, Liboni A (2008) Inflammation in venous disease. Int Angiol 27:361–369PubMedGoogle Scholar
  25. 25.
    Lafeber FP, Miossec P, Valentino LA (2008). Physiopathology of haemophilic arthropathy. Haemophilia 14 Suppl 4:3–9CrossRefPubMedGoogle Scholar
  26. 26.
    Shenkar R, Schwartz MD, Terada LS, Repine JE, McCord J, Abraham E (1996) Hemorrhage activates NF-kappa B in murine lung mononuclear cells in vivo. Am J Physiol 270:L729–L735PubMedGoogle Scholar
  27. 27.
    Meldrum DR, Shenkar R, Sheridan BC, Cain BS, Abraham E, Harken AH (1997) Hemorrhage activates myocardial NFkappaB and increases TNF-alpha in the heart. J Mol Cell Cardiol 29:2849–2854CrossRefPubMedGoogle Scholar
  28. 28.
    Willerson JT, Ridker PM (2004) Inflammation as a cardiovascular risk factor. Circulation 109:II-2–II-10CrossRefGoogle Scholar
  29. 29.
    Lindmark E, Diderholm E, Wallentin L, Siegbahn A (2001) Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. Jama 286:2107–2113CrossRefPubMedGoogle Scholar
  30. 30.
    Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L (2000) Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 343:1139–1147CrossRefPubMedGoogle Scholar
  31. 31.
    Libby P (2008) Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 121:S21–S31CrossRefPubMedGoogle Scholar
  32. 32.
    Dvorakova A, Poledne R (2004) Influenza–a trigger for acute myocardial infarction. Atherosclerosis 172:391CrossRefPubMedGoogle Scholar
  33. 33.
    Bainton D, Jones GR, Hole D (1978) Influenza and ischaemic heart disease–a possible trigger for acute myocardial infarction? Int J Epidemiol 7:231–239CrossRefPubMedGoogle Scholar
  34. 34.
    Goerge T, Ho-Tin-Noe B, Carbo C, Benarafa C, Remold-O’Donnell E, Zhao BQ, Cifuni SM, Wagner DD (2008) Inflammation induces hemorrhage in thrombocytopenia. Blood 111:4958–4964CrossRefPubMedGoogle Scholar
  35. 35.
    Li G, Keenan AC, Young JC, Hall MJ, Pamuklar Z, Ohman EM, Steinhubl SR, Smyth SS (2007) Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils. Arterioscler Thromb Vasc Biol 27:1850–1856CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Charles L. Campbell
    • 1
    • 2
  • Steven R. Steinhubl
    • 3
  • William C. Hooper
    • 5
  • Joseph Jozic
    • 6
  • Susan S. Smyth
    • 1
    • 2
  • Debra Bernstein
    • 4
  • Christine De Staercke
    • 5
  • George Syros
    • 7
  • Brian H. Negus
    • 8
  • Thomas Stuckey
    • 9
  • Gregg W. Stone
    • 7
  • Roxana Mehran
    • 10
  • George Dangas
    • 11
  1. 1.Gill Heart InstituteUniversity of KentuckyLexingtonUSA
  2. 2.Lexington VA Medical CenterLexingtonUSA
  3. 3.Geisinger Medical CenterDanvilleUSA
  4. 4.The Medicines Company ParsippanyUSA
  5. 5.Centers for Disease ControlAtlantaUSA
  6. 6.Harrington-McLaughlin Heart & Vascular Institute University Hospitals Case Medical CenterClevelandUSA
  7. 7.Columbia University Medical Center and the Cardiovascular Research FoundationNew YorkUSA
  8. 8.Chattanooga Heart InstituteChattanoogaUSA
  9. 9.LeBauer Cardiovascular Research FoundationGreensboroUSA
  10. 10.Mount Sinai Medical Center, Cardiovascular InstituteNew YorkUSA
  11. 11.Cardiovascular InstituteMount Sinai HospitalNew YorkUSA

Personalised recommendations